A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Latest Information Update: 15 Jul 2024
At a glance
- Drugs M-254 (Primary) ; Immune globulin
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors Momenta Pharmaceuticals
- 01 Jul 2024 According to ClinicalTrials.gov record, 4 new Pharmacokinetic primary endpoint has been added.
- 19 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 02 Aug 2021 Status changed from recruiting to discontinued.